免疫捕獲軍團(tuán)菌檢測試劑盒

廣州健侖生物科技有限公司

主要用途：用于檢測尿樣中嗜肺軍團(tuán)菌血清型1抗原，以支持軍團(tuán)菌感染的診斷。

產(chǎn)品規(guī)格：20T/盒

存儲(chǔ)條件：2-30℃

免疫捕獲軍團(tuán)菌檢測試劑盒

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、西尼羅河、立克次體、無形體、蜱蟲、恙蟲、利什曼原蟲、RK39、漢坦病毒、深林腦炎、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

【產(chǎn)品介紹】

二維碼掃一掃

【公司名稱】 廣州健侖生物科技有限公司
【】    楊永漢 
【】 
【騰訊 】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-3室
【企業(yè)文化】

盡管，科學(xué)家們強(qiáng)調(diào)研究的抗原抗體癌和肺癌樣本的數(shù)量很小，在每種情況下間質(zhì)HSF1激活與患者不良預(yù)后之間的強(qiáng)關(guān)聯(lián)確保了開展更深入的臨床調(diào)查。他們補(bǔ)充說，一種基于HSF1的生物標(biāo)記物有可能幫助預(yù)測出哪些患者的腫瘤，尤其是早期的肺癌zui有可能發(fā)展，并有可能從更積極的治療中獲益。相反，這樣的信息還可以防止罹患不太具有侵襲性癌癥的患者經(jīng)受高毒性的治療方法“過度治療”所導(dǎo)致的副作用。
長久以來，人們認(rèn)為，DNA突變不但是癌癥，而且也是生物體進(jìn)化改變的燃料，被認(rèn)為是整個(gè)基因組隨機(jī)發(fā)生的罕見事件。
然而，zui近的研究表明，癌癥發(fā)展經(jīng)常涉及同時(shí)產(chǎn)生且彼此靠近的多個(gè)突變的形成。這些基團(tuán)簇突變經(jīng)常被發(fā)現(xiàn)于染色體重排發(fā)生區(qū)域。
相關(guān)文章發(fā)表于《Cell Reports》雜志上，可能有一天會(huì)導(dǎo)致新的癌癥療法。根據(jù)愛荷華大學(xué)的一個(gè)生物學(xué)家和她的同事們，以及由環(huán)境衛(wèi)生科學(xué)研究所的高級(jí)助理研究員Dmitry Gordenin所的一個(gè)研究組的研究表明。
基團(tuán)簇突變的形成可能是由于DNA修復(fù)的過程。
自由藝術(shù)與科學(xué)的UI學(xué)院的生物學(xué)副教授Anna Malkova指出，DNA修復(fù)途徑，被稱為斷裂誘導(dǎo)復(fù)制(BIR)，可以促進(jìn)DNA團(tuán)的突變。
“以前，我們已經(jīng)表明，雙鏈DNA斷裂(這可以產(chǎn)生氧化，電離輻射和復(fù)制錯(cuò)誤)，可以通過BIR修復(fù)，” Malkova說。
“在BIR期間，斷裂DNA的末端與另一個(gè)染色體上的相同的DNA序列配對(duì)，并啟動(dòng)一個(gè)不同尋常類型的復(fù)制，和遷移泡沫一樣的行進(jìn)，并與大量的單鏈DNA的積累有關(guān)，” 她說。
在本研究中，研究人員研究了遭受到烷化劑(細(xì)胞的殺傷劑)傷害的酵母細(xì)胞的BIR過程。“我們發(fā)現(xiàn)，BIR過程中的單鏈DNA積累容易受到導(dǎo)致基團(tuán)簇突變形成的傷害，”文章的另一*作者、 UI博士后 Cynthia Sakofsky解釋道，“這些基團(tuán)簇與在人類癌癥中發(fā)現(xiàn)的相似。”

Although scientists underscore the small number of antigen-antibody and lung cancer samples studied, the strong association between interstitial HSF1 activation and poor prognosis in each patient led to a deeper clinical investigation. They add that a HSF1-based biomarker may help predict which patients' tumors, especially early-stage lung cancer, are most likely to develop and may benefit from more aggressive treatment. Conversely, such information can also prevent side effects caused by "over-treatment" of patients with less aggressive cancers undergoing hyper-toxic treatments.
It has long been believed that DNA mutations are not only cancers, but also fuels of evolutionary changes in organisms, and are thought to be a rare event in which the entire genome is randomly generated.
However, recent studies show that cancer development often involves the formation of multiple mutations that are produced simultaneously and close to each other. These cluster mutations are often found in chromosomal rearrangements.
Related articles in the Cell Reports magazine may one day lead to new cancer therapies. According to a study by a biologist and her colleague at the University of Iowa and a research team led by Dmitry Gordenin, senior assistant researcher at the Institute of Environmental Health Sciences.
The formation of cluster mutations may be due to the process of DNA repair.
Anna Malkova, associate professor of biology at the Free Academy of Arts and Sciences's UI Institute, points out that the DNA repair pathway, known as fracture-inducible replication (BIR), promotes mutations in DNA clusters.
"In the past, we have shown that double-stranded DNA breaks (which can produce oxidation, ionizing radiation and replication errors) that can be repaired by BIR," Malkova said.
"During BIR, the ends of the cleaved DNA pair with the same DNA sequence on another chromosome and initiate an unusual type of replication that travels like a migrating foam and is associated with the accumulation of large quantities of single-stranded DNA," she said Say.
In this study, researchers studied the BIR process of yeast cells that were damaged by alkylating agents (cell killers). "We found that single-stranded DNA accumulation during BIR is vulnerable to damage caused by cluster mutations," explained Cynthia Sakofsky, UI postdoctoral fellow at the UI. "These clusters are associated with the discovery in human cancers Similar. "